Nuclear Medicine & Radiation Therapy

Biography

Biography: Barry J Allen

Abstract

Prostate cancer claimed an estimated 136,500 lives globally in 2011. Recurrent disease is usually treated with androgen deprivation therapy (ADT), which provides outstanding early but transient control of progression. The tragedy here is that the benefits of ADT are lost within 2 years for most men as the cancer progresses to an incurable “late-stage” castrate resistant form of the disease (CRPC) with median survival of ~18 months. The minimal residual disease states derived from prostatectomy and ADT provide clear windows of opportunity for an effective systemic adjuvant therapy with minimal side effects. Targeted alpha therapy (TAT) is such a therapy, where antibodies specific for cancer biomarkers are labelled with alpha-radionuclides to more efficiently kill cancer cells with reduced adverse events. The success of systemic TAT in clinical trials for advanced metastatic melanoma indicates efficacy with minimal side effects. rnImproved molecular profiling of tumours now allows for therapies like TAT to be personalized for the patient’s cancer, leading to the next generation of adjuvants for the treatment of minimal residual disease states following prostatectomy and ADT. This paper examines the preclinical and clinical efficacy of TAT with c595 and J591 monoclonal antibodies, labelled with beta or alpha emitting radioisotopes, and its potential as an adjunctive therapy for the management of residual prostate cancerrn